Notice of Allowability	Application No.	Applicant(s)
	09/453,234	BUECHLER ET AL.
	Examiner	Art Unit
	Quang Nguyen, Ph.D.	1636
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included nerewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. This communication is responsive to 1/16/04.		
2. X The allowed claim(s) is/are <u>1-34</u> .		
3. The drawings filed on are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. 🔯 CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) ☐ hereto or 2) ☑ to Paper No./Mail Date <u>5</u> .		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948)	5.	
 Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 		ment/Comment
4. Examiner's Comment Regarding Requirement for Deposit	8. X Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.	

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with attorney Joe Liebeschuetz on March 31, 2004.

Amended claims 1-34 are pending in the present application. The application has been amended as follows:

In the Specification:

On page 5, line 10, please replace the term "Fig. 4" with - - Fig. 4A-B - -.

In the Claims:

Claims 5, 8-9 and 23 have been amended as follows:

Claim 5: The method of claim 1, wherein the nucleic acids encode variable regions of the antibody chains and the display package comprises a segment encoding a human constant region and [the cloning joins] wherein a nucleic acid encoding a variable region is joined in-frame with the segment encoding the human constant region.

Claim 8: The method of claim_1, wherein the antibody chain comprises a heavy or light chain which in at least some library members is complexed to a binding partner, comprising respectively a partner light or heavy human chain to form a Fab fragment.

Application/Control Number: 09/453,234

Art Unit: 1636

Claim 9: The method of claim 1, further comprising contacting [libraries]

Page 3

library members with a target, whereby library members displaying an antibody chain

and binding partner [(if present)], if present, with specific affinity for the target bind to the

target, and separating display packages displaying antibody chains bound to the target

to produce a subpopulation of display packages.

Claim 23: The method of claim 17, further comprising contacting [libraries]

library members from the display library with a target, whereby library members

displaying a Fab fragment with specific affinity for the target bind to the target, and

separating phage displaying Fab fragments bound to the target to produce a further

subpopulation of phage.

Application/Control Number: 09/453,234 Page 4

Art Unit: 1636

REASONS FOR ALLOWANCE:

The following is an examiner's statement of reasons for allowance: The prior art of record does not teach or fairly suggests a method of producing a human antibody display library or a method of producing a human Fab phage display library as claimed. Accordingly, the claims are allowable over the prior art of record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Quang Nguyen, Ph.D., whose telephone number is (571) 272-0776.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's mentor, David Guzo, Ph.D., may be reached at (571) 272-0767, or SPE, Irem Yucel, Ph.D., at (571) 272-0781.

To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1636; Central Fax No. (703) 872-9306.

Quang Nguyen, Ph.D.

PRIMARY EXAMINER